Our Mission

Zula is dedicated to repurposing recombinant leptin (metreleptin) as a groundbreaking treatment for anorexia nervosa, the deadliest mental health disease.

The Challenge

Anorexia nervosa has the highest mortality rate among psychiatric diseases, with no approved drugs available for treatment.

Our Solution

Building on the pioneering work at the University of Duisburg-Essen and University of Zurich, Zula has licensed patents to advance this life-saving therapy.

Our Approach

As a Delaware Public Benefit Corporation, Zula is committed to expediting access to affordable medical products for patients with unmet needs.

Clinical Partners

We're collaborating with leading experts to conduct clinical trials and establish randomized evidence for metreleptin as an anorexia nervosa treatment.

Join Our Journey

Zula is actively seeking partnerships and funding to manufacture metreleptin, conduct clinical trials, and make this potentially life-saving treatment accessible and affordable for those in need.